Sol-Gel Technologies Reports Q1 2025 Financial Results

Sol-Gel Technologies ( (SLGL) ) has provided an update.

On May 23, 2025, Sol-Gel Technologies announced its financial results for the first quarter of 2025, reporting a total revenue of $1 million, an increase from $0.5 million in the same period in 2024. The company experienced a net loss of $8.8 million, with increased research and development expenses primarily due to manufacturing development for SGT-610 and commercialization efforts for EPSOLAY and TWYNEO outside the U.S. Sol-Gel’s cash resources are expected to fund operations into the first quarter of 2027, indicating a stable financial outlook despite the losses.

The most recent analyst rating on (SLGL) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Sol-Gel Technologies stock, see the SLGL Stock Forecast page.

Spark’s Take on SLGL Stock

According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.

Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.

To see Spark’s full report on SLGL stock, click here.

More about Sol-Gel Technologies

Sol-Gel Technologies, Ltd. is a clinical-stage dermatology company focused on developing and commercializing drug products for skin diseases. The company has developed FDA-approved products TWYNEO for acne vulgaris and EPSOLAY for rosacea. Sol-Gel’s pipeline includes SGT-610 for Gorlin syndrome and SGT-210 for rare skin keratodermas.

Average Trading Volume: 25,496

Technical Sentiment Signal: Sell

Current Market Cap: $21.41M

For a thorough assessment of SLGL stock, go to TipRanks’ Stock Analysis page.